ClinicalTrials.gg

Program

mirvetuximab soravtansine

Also written as “Mirvetuximab Soravtansine”, “Mirvetuximab soravtansine” and “TAK-853”.

Its studies are mostly in Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Fallopian Tube Neoplasms · Neoplasms, led by 5 companies.

Furthest: phase 3, since Dec 10, 201515 company-led studies, 8 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie115 open or runningphase 3since Dec 10, 2015May 30, 2012Nov 2026phase 2 · NCT05456685
AGO Research11 open or runningphase 2since Feb 10, 2020Feb 10, 2020none ahead
Huadong Medicine10 open or runningphase 3since Nov 14, 2022Nov 14, 2022none ahead
Pheast Therapeutics11 open or runningphase 1since Feb 10, 2025Feb 10, 2025Apr 2029phase 1 · NCT06840886
Takeda11 open or runningphase 2since Apr 26, 2024Apr 26, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since May 30, 2012.

  1. Nov 6, 2015Phase 2 study in Carcinoma, Ovarian EpithelialAbbVie · NCT02606305 · 264 enrolled · United States, Belgium, Canada and more
  2. Dec 10, 2015Phase 3 study in Carcinoma, Ovarian EpithelialAbbVie · NCT02631876 · 366 enrolled · United States, Belgium, Bosnia and Herzegovina and more
  3. Dec 17, 2019Phase 3 study in Carcinoma, Ovarian EpithelialAbbVie · NCT04209855 · 453 enrolled · United States, Australia, Belgium and more
  4. Feb 10, 2020AGO Research’s first study: phase 2 study in Recurrent Epithelial Ovarian, Fallopian or Peritoneal CarcinomaNew to AGO ResearchAGO Research · NCT04274426 · 136 enrolled · Germany
  5. Feb 27, 2020Phase 3 study in Carcinoma, Ovarian EpithelialAbbVie · NCT04296890 · 106 enrolled · United States, Australia, Belgium and more
  6. Aug 24, 2021Phase 2 study in Ovarian NeoplasmsAbbVie · NCT05041257 · 79 enrolled · United States, Australia, Belgium and more
  7. Jun 29, 2022Phase 2 study in Fallopian Tube NeoplasmsAbbVie · NCT05456685 · 125 enrolled · United States, Belgium, Canada and more
  8. Jun 30, 2022Phase 3 study in Ovarian NeoplasmsAbbVie · NCT05445778 · 520 enrolled · United States, Argentina, Australia and more
  9. Nov 14, 2022Huadong Medicine’s first study: phase 3 study in Carcinoma, Ovarian EpithelialNew to Huadong MedicineHuadong Medicine · NCT05622890 · 35 enrolled · China
  10. Apr 26, 2024Takeda’s first study: phase 2 study in Ovarian NeoplasmsNew to TakedaTakeda · NCT06390995 · 28 enrolled · Japan
  11. Nov 8, 2024Phase 2 study in Fallopian Tube NeoplasmsAbbVie · NCT06682988 · 110 planned · United States, Australia, Belgium and more
  12. Feb 10, 2025Pheast Therapeutics’ first study: phase 1 study in Ovarian NeoplasmsNew to Pheast TherapeuticsPheast Therapeutics · NCT06840886 · 426 planned · United States
  13. Mar 20, 2025Phase 2 study in Carcinoma, Ovarian EpithelialAbbVie · NCT06890338 · 140 planned · United States
  14. Jul 2, 2025Phase 2 study in Ovarian NeoplasmsAbbVie · NCT07059845 · 400 planned · United States, Australia, Belgium and more

Ahead

  1. Nov 2026Primary completion: phase 2 study in Fallopian Tube NeoplasmsAbbVie · NCT05456685
  2. Apr 2027Primary completion: phase 3 study in Ovarian NeoplasmsAbbVie · NCT05445778
  3. Jan 2029Primary completion: phase 2 study in Ovarian NeoplasmsAbbVie · NCT07059845
  4. Apr 2029Primary completion: phase 1 study in Ovarian NeoplasmsPheast Therapeutics · NCT06840886

TargetBeta

FOLR1 →read by rule
“An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) ”NCIt, by rule
“Folate receptor alpha binding agent”ChEMBL 37, by rule

Other programs on FOLR1

ProgramCompanyFurthest phaseStudies
rinatabart sesutecanruleGenmabphase 39
torvutatug samrotecanAstraZenecaphase 35
sofetabart mipitecanEli Lillyphase 32
opugotamig olatansineAbbViephase 22
Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901AbbViephase 11
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928ruleteneoseven-incphase 11

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07059845Ovarian Neoplasms · United States, Australia, Belgium and more2RecruitingAbbVieJan 2029400
NCT06890338Carcinoma, Ovarian Epithelial · United States2RecruitingAbbVieFeb 2030140
NCT06840886Ovarian Neoplasms · United States1RecruitingPheast TherapeuticsApr 2029426
NCT06682988Fallopian Tube Neoplasms · United States, Australia, Belgium and more2RecruitingAbbVieJul 2026110
NCT06390995Ovarian Neoplasms · Japan2Active, not recruitingTakedaApr 16, 202528
NCT05622890Carcinoma, Ovarian Epithelial · China3UNKNOWNHuadong MedicineApr 30, 202335
NCT05445778Ovarian Neoplasms · United States, Argentina, Australia and more3Active, not recruitingAbbVieApr 2027520
NCT05456685Fallopian Tube Neoplasms · United States, Belgium, Canada and more2Active, not recruitingAbbVieNov 2026125
NCT05041257Ovarian Neoplasms · United States, Australia, Belgium and more2CompletedAbbVieDec 12, 202479
NCT04296890Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more3CompletedAbbVieNov 16, 2021106
NCT04274426Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma · Germany2Active, not recruitingAGO ResearchDec 3, 2025136
NCT04209855Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more3CompletedAbbVieMar 6, 2023453
NCT02631876Carcinoma, Ovarian Epithelial · United States, Belgium, Bosnia and Herzegovina and more3CompletedAbbVieJan 2019366
NCT02606305Carcinoma, Ovarian Epithelial · United States, Belgium, Canada and more2CompletedAbbVieMar 12, 2021264
NCT01609556Neoplasms · United States, Canada1CompletedAbbVieMar 19, 2018206

How it is read

Names in the registry

  • “Mirvetuximab Soravtansine”, 8 entries
  • “Mirvetuximab soravtansine”, 5 entries
  • “TAK-853”, 1 entry
  • “Mirvetuximab soravtansine plus Bevacizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.